The aim of the Education Committee (EC) is to coordinate ESOT’s efforts to advance multidisciplinary education for transplant professionals at all career levels and to contribute to their professional development.
The Basic Science Committee promotes scientific issues and transplantation research within ESOT. An active basic science community and an efficient translation of innovation into the clinic are crucial for the future of transplantation medicine.
The European Transplant Allied Healthcare Professionals (ETAHP) reaches out to allied healthcare professionals throughout Europe in order to ensure the best care possible for all transplant patients, with the aim to optimize patient outcomes.
The Young Professionals in Transplantation (YPT) is the Network for Junior Transplant professionals of ESOT, representing all young transplant clinicians and scientists who are beginning a career in transplantation and organ donation.
The mission of ECTORS is to provide a forum for discussing and stimulating novel developments in the fields of cellular therapies in organ transplantation, organ regeneration and generation of new organs from stem cells and biomaterials.
ECTTA is the forum for experience exchange on treatment of patients with end-stage heart and lung failure. Our aim is to improve outcomes for the patients.
EDTCO aims to support health care professionals to provide clinically effective programmes on organ and tissue donation, procurement and transplantation.
EKITA is the Organ Expert Section of ESOT on kidney transplantation in Europe, providing a forum for kidney transplantation professionals to exchange scientific information and views aimed at providing the best service to European patients .
The European Liver and Intestine Transplant Association (ELITA), previously known as the European Liver Transplant Association (ELTA), is a section of ESOT. Its membership represents the expertise on liver and intestinal transplantation in Europe.
ELPAT is a European platform that brings continuity and progress in European research and dialogue on "Ethical, Legal and Psychosocial Aspects of organ Transplantation". ELPAT currently consists of over 160 experts from more than 25 European countries.
EPITA is established to provide a forum for those working in the field of pancreas and islet of Langerhans transplantation or any other alternative form of beta cell replacement in Europe, to exchange scientific information and views related primarily to providing the best service for patients in Europe requiring pancreas or islet transplantation.
VCA has opened a new era in the field of transplantation, reconstructive and restorative surgery. This Section brings together 10 representatives of major European teams at the forefront in this field.
Moderated by Chair Robin Vos and Co-Chair Irene Bello, this webinar will provide an up-to-date overview of Chronic Lung Allograft Dysfunction (CLAD), the most common post-transplant problem in lung transplant patients. CLAD is a burning matter in lung transplantation, limiting long-term survival in approximately 50% of patients at 5 years post-transplantation. This webinar will elaborate on the recently updated definition and diagnosis of CLAD and how this will assist in accelerating progress in achieving uniform management between centres and facilitate clinical trials. The importance of personalised treatment and preventative strategies will be highlighted, as well as current unmet needs in the field. The webinar will also cover histopathology, risk factors and therapeutic interventions of CLAD, to offer transplant healthcare practitioners a state-of-the-art overview of the best practice in the management of CLAD.
18.00 – 18.05: Introduction, Robin Vos, Chair & Irene Bello, Co-Chair
18.05 – 18.15: Definition and diagnosis, Geert Verleden (Leuven, BE)
18.15 – 18.25: Histopathology, Jan von der Thüsen (Rotterdam, NL)
18.25 – 18.35: Risk factors, Berta Saez (Barcelona, ESP)
18.35 – 18.45: Treatment, Jens Gottlieb (Hannover, DE)
18.45 – 18.55: Prevention, Olivier Brugière (Paris, FR)
18.55 – 19.05: Q&A, Robin Vos, Chair & Irene Bello, Co-Chair